Biocryst Pharmaceuticals Profit Margin

Biocryst Pharmaceuticals (BCRX) currently reports a profit margin of -40.9% as of June 2026. That compares with -6.41% in the prior-year period — down 538.5% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Biocryst Pharmaceuticals's profit margin history and peer comparisons.

Biocryst Pharmaceuticals's profit margin decreased from -6.41% to -40.9% — a 538.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Biocryst Pharmaceuticals's profit margin of -40.9% is lower than the Healthcare sector average of 13.89%. That is roughly 394.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Biocryst Pharmaceuticals's current -40.9% should be judged against Healthcare norms (sector average: 13.89%) and against BCRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -40.9%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Biocryst Pharmaceuticals, and consider following BCRX for alerts when major investors trade the stock.